New York, NY (March 20, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (ADCETRIS®) in combination with chemotherapy for the treatment of adults with previously untreated Stage III or IV classical…
Lymphoma Research Foundation Publishes White Paper to Outline Key Issues Discussed During Second Oral Therapies Workshop In October 2017, The Lymphoma Research Foundation (LRF) convened its second Adherence and Oral Therapies in Lymphoma and CLL Workshop with a diverse faculty to…
This month, the Lymphoma Research Foundation endorsed the bipartisan Cancer Care Planning and Communications (CCPC) Act. Co-Sponsored by U.S. Congressmen Mark DeSaulnier (D-CA) and Ted Poe (R-TX), the CCPC Act would establish a new Medicare service for cancer care planning. …
Lymphoma Research Foundation Launches Redesigned Site to Better Serve the Lymphoma and CLL Community New York, NY (March 2018) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding the most promising young lymphoma investigators…
Oral medications are being increasingly used to treat patients with lymphoma and chronic lymphocytic leukemia (CLL). Five oral drugs have been approved over the past three years for eight different indications in lymphoma and CLL. Many patients report numerous advantages…
New York, NY (October 19, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of axicabtagene ciloleucel (YescartaTM, Kite, a Gilead Company) to treat patients with large B-cell lymphoma who have relapsed or have…
LRF Scientific Advisory Board Members to be Joined by Current and Former Grantees at the 59th ASH Annual Meeting & Exposition New York, NY (December 7, 2017) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of obinutuzumab (Gazyva®) to treat patients with previously untreated advanced follicular lymphoma (FL). Under the new indication, patients with stage II…
New York, NY (November 9, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (ADCETRIS®) to treat patients with certain types of cutaneous T-cell lymphoma (CTCL) who have received at least one…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of acalabrutinib (CALQUENCE) to treat patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The Bruton…